Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To establish whether 800 mg Gleevec/Glivec (as 400 mg bid) improves efficacy in newly diagnosed, previously untreated CML-CP patients as compared to 400 mg by the evaluation of the rate of molecular response defined as Bcr-Abl ratio ≤0.1% (≥ 3 log reductionof Bcr-Abl transcropts from a standardized baseline) as detected by RT-PCR at 12 months.
Critère d'inclusion
- Newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)